Natural Killer Cells Manufacturing

Many studies are evaluating natural killer (NK) cells as potential cancer treatments. However, it is challenging to obtain primary human NK cells at clinically relevant scale. Here, we generated 1 × 10⁹ cells in a workflow amenable to a current good manufacturing practices (cGMP) environment.

Learn the workflow for xeno‑free natural killer cell expansion from leukapheresis units. The process incorporates several automated and functionally closed unit operations. Overall, the methodology presented here is compatible with industrial workflows for natural killer cell manufacturing. Follow the feasibility of xeno‑free NK cell expansion, closure of key unit operations, and how future work could focus on fine‑tuning each step to generate a robust, scalable process.